Induced Pluripotent Stem Cells: Global Markets

Induced Pluripotent Stem Cells: Global Markets

  • June 2017 •
  • 139 pages •
  • Report ID: 2212008
• The global market for induced pluripotent stem cells (iPSCs) reached $2.1 billion in 2016. The market should reach $3.6 billion in 2021, increasing at a compound annual growth rate (CAGR) of 11.6% from 2016 through 2021.
• The U.S. market for iPSCs reached over $1.0 billion in 2016. The market should reach $1.8 billion in 2021, increasing at a CAGR of 11.3% from 2016 through 2021.
• Asia-Pacific market for iPSCs reached $449 million in 2016. The market should reach $854 million in 2021, increasing at a CAGR of 12.3% from 2016 through 2021.

Chapter 1: Introduction

Study Goals and Objectives
The aim of this report is to provide detailed market and industry analyses to help readers quantify and qualify the global market for induced pluripotent stem cells (iPSCs). Important trends in the field and market segments are identified, and market sizes and sales forecasts by segmented markets are provided through 2021. This report focuses on the market side rather than the technical side. The detailed market segmentation, market shares, major drivers, trend analysis and forecasts for the entire iPSCs market are analyzed.

Reasons for Doing This Study
Detailed market and industry analysis for the iPSCs market is needed. As a breakthrough technology recognized by the Nobel Prize in Physiology or Medicine 2012, iPSCs technology may bring a revolutionary change to modern medicine. Great opportunities always exist with high risks, but the detailed analysis and forecasts of the iPSC market can provide useful information for all management levels to help make strategic decisions in related areas. iPSC-related products are forming an emerging market despite the fact that iPSC clinical applications are still at their early stage. The potential scope of the iPSC market is becoming clear, and it is appropriate to review the emerging market, see the current size and share of each segment, evaluate the market trends and look to its future.

Intended Audience
This report is designed to satisfy the information needs of various individuals involved in the biological research, pharmaceutical and regenerative medicine marketplaces, including senior management corporate executives seeking to base their strategic decisions on the best available information on market forces and trends. It is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background material on the marketplaces associated with the induced pluripotent stem cells with which they are operating. This report was prepared as a study of the global market for induced pluripotent stem cells. Information is presented with a specific focus on the various market segments, including those based on product type, product function, application, geography and technological method. The detailed segmentation is to provide a deep profile of the global iPSCs market, upon which the market forecasts are made.

This study will be of significant interest to academic institutions, hospitals, biotech and pharmaceutical companies, biopharmaceutical researchers, marketing executives from pharmaceutical and biotech companies, contract research organizations, biologists, chemists, physicians, pharmaceutical directors, product managers and representatives, and all manner of institutional directors from either public or private entities. It will also be of interest to investment bankers in the biotechnology and pharmaceutical sectors, insurance executives and life sciences product marketing managers.

Scope of Report
This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered. For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis; iPSC-derived cell-type-based market segments include cardiomyocytes, hepatocytes, neurons, endothelia cells and other cell types; geography-based market segments include the U.S., Europe, Asia-Pacific and Rest of World. Research and market trends are also analyzed by studying the funding, patent publications and research publications in the field.

Both primary and secondary research methodologies were used to prepare this study. Primary research includes interviews with leading individuals in stem cell companies and industry associations. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources that were critically assessed by BCC Research.

Information Sources
Information sources included marketing strategists, industry executives, academic experts, government agencies and regulatory bodies, and surveys of scientists in both academic and industrial areas. Company annual reports and Securities and Exchange Commission (SEC) filings, journal articles, newsletters, expert blogs and data from related institutions were also reviewed.

Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:
United States
• California
• Massachusetts
• New York
• Wisconsin
• Other States

Rest of World

Country=World Industry=BiologicalTherapy ParentIndustry=LifeSciences Date=201706 Topic=MarketShares Publisher=BCCResearch Price=5000